| Filed On | Filing |
|---|---|
| 20 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 19, 2026, is entered into by and among First Tracks Biotherapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (ind... |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS SECURITIES PURCHASE AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 19... |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms |
| 12 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 22 Jun 2026 | 8-K: Entry into a Material Definitive Agreement |
| 14 May 2026 | 8-K: Results of Operations and Financial Condition |
| 20 Apr 2026 | 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +6 more |
| 03 Apr 2026 | 8-K: Regulation FD Disclosure |
Loading...
